Remove Development Remove Genome Project Remove Life Science
article thumbnail

The cluster effect: Connectivity and collaboration in life sciences hubs

Pharmaceutical Technology

From the Human Genome Project to contemporary drug development, collaboration is critical to the life sciences. It is also an important factor in the success of life sciences clusters, where a high concentration of pharmaceutical or medical device companies can all be found in one district, city or region.

article thumbnail

Seqera Labs partners with Genomics England to enhance genomic research capabilities

Drug Discovery Today

BARCELONA/LONDON, 25.05.23: Seqera Labs, the leading provider of secure workflow orchestration software in the life sciences sector, has partnered with Genomics England, the government-owned company that launched the 100,000 Genomes Project in partnership with the NHS.

Genome 45
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bioinformatics Jobs: How to Succeed in This Competitive Space

XTalks

Bioinformatics jobs are commonly found in the fields of computer information science, pharmaceuticals, biotechnology, medical technology, computational biology, proteomics and medical informatics. The Human Genome Project could not have succeeded without the use of bioinformatics. How to Become a Bioinformatics Analyst.

article thumbnail

Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics

Roots Analysis

70+ spatial Genomics solutions are developed by industry and non-industry players. Presently, over 45 industry and non-industry players across the globe are engaged in the development of spatial omics solutions for spatial phenotyping and profiling of cellular landscape. The trend is unlikely to change in the foreseen future.

Genome 52
article thumbnail

Exa-Cel CRISPR Gene Therapy for Sickle Cell Disease Deemed Safe by FDA Advisory Panel

XTalks

The scientists on the advisory committee were particularly focused on the CRISPR gene editing technology itself and how companies like Vertex that are developing CRISPR-based therapies are ensuring their treatments are not making off-target gene edits. The panel did not have to vote on the risk-benefit profile of the treatment in the meeting.

article thumbnail

Genomics England will move HQ to Canary Wharf’s new biocluster

pharmaphorum

Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development. The new building is just the first project for the initiative, located on a 3.3

Genome 111
article thumbnail

Unlocking disease treatment with large-scale research

pharmaphorum

Ben Hargreaves examines why a research project in the UK could provide key insights to develop treatments against many of the most prominent diseases impacting society. There are also hopes that clues could be found as to what risk factors are involved in the development of the most difficult to understand diseases.